Actuate Therapeutics (ACTU) Capital Expenditures (2024 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Capital Expenditures of -$110548.0 for Q1 2025, down 200.0% quarter-over-quarter from $110548.0 in Q4 2024.
Actuate Therapeutics (ACTU) Capital Expenditures (2024 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Capital Expenditures for 2 consecutive years, with -$110548.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Capital Expenditures changed N/A year-over-year to -$110548.0; the TTM figure through Dec 2025 stood at -$110548.0 (down 200.0% YoY), while the FY2025 annual figure was -$110548.0, down 200.0% from the prior year.
- Capital Expenditures retreated to -$110548.0 in Q1 2025 per ACTU's latest filing, from $110548.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $110548.0 in Q4 2024 and bottomed at -$110548.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -110,548.00 |
| Mar 31, 2025 | -110,548.00 |
| Dec 31, 2024 | 110,548.00 |
| Dec 31, 2024 | 110,548.00 |